Summit Therapeutics Inc. - SMMT STOCK NEWS

Summit Therapeutics (NASDAQ: SMMT) announced positive results from the Phase III HARMONi-2 trial of ivonescimab, a novel bispecific antibody, in first-line treatment of PD-L1 positive advanced NSCLC. The trial showed:

- 49% reduction in risk of disease progression or death compared to pembrolizumab
- Median PFS of 11.14 months vs 5.82 months for pembrolizumab
- Benefits across subgroups, including PD-L1 high and low expression
- Comparable safety profile to pembrolizumab

Summit plans to initiate HARMONi-7, a Phase III trial in first-line PD-L1 high advanced NSCLC, in early 2025. Additional Phase II data in other solid tumors will be presented at ESMO 2024.

Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards to five new employees, consisting of options to purchase up to 102,000 shares of common stock. These awards, approved by the Company's Compensation Committee, were made in accordance with Nasdaq Listing Rule 5635(c)(4). The options, granted on September 4, 2024, have a ten-year term and an exercise price of $12.00 per share, matching the closing price of Summit's common stock on that date. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement.

Summit Therapeutics (NASDAQ: SMMT) announced that the primary analysis of the Phase III HARMONi-2 trial for ivonescimab, their novel bispecific antibody, will be presented at WCLC 2024. The trial compared ivonescimab monotherapy to pembrolizumab monotherapy in patients with advanced NSCLC and positive PD-L1 expression. Ivonescimab achieved a statistically significant improvement in progression-free survival (PFS) across various clinical subgroups. This marks the first drug to show clinically meaningful benefit over pembrolizumab in a randomized Phase III NSCLC trial. Additionally, Phase II data on ivonescimab in the perioperative setting for resectable NSCLC will be presented.

Akeso, Inc. (HKEX: 9926.HK) announced two upcoming oral presentations of ivonescimab (PD-1/VEGF bispecific antibody) at the IASLC 2024 World Conference on Lung Cancer (WCLC24). A key presentation will feature results from the HARMONi-2/AK112-303 study, comparing ivonescimab monotherapy to pembrolizumab in patients with PD-L1 positive non-small cell lung cancer (NSCLC).

Ivonescimab has shown significant milestones, including:

• Marketing approval for EGFR-mutated NSCLC treatment in May 2024
• Statistically significant improvement in progression-free survival compared to pembrolizumab
• Acceptance of supplemental New Drug Application by China NMPA for first-line treatment of PD-L1 positive NSCLC

These developments position ivonescimab as a promising treatment option in the field of lung cancer therapy.

Summit Therapeutics (NASDAQ: SMMT) has announced the grant of inducement awards to 14 new employees. The awards consist of options to purchase a total of 453,250 shares of common stock. These options, approved by the Company's Compensation Committee, were granted on August 7, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have a ten-year term and an exercise price of $9.40 per share, which was the closing price of Summit's common stock on the grant date. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement to be executed by each recipient.

Summit Therapeutics (NASDAQ: SMMT) reported financial results and operational progress for Q2 and H1 2024. Key highlights include:

1. Ivonescimab achieved statistically significant improvement over pembrolizumab in HARMONi-2 Phase III trial for 1L advanced NSCLC.

2. Positive HARMONi-A data presented at ASCO and published in JAMA, supporting ivonescimab's first regulatory approval in China for 2L+ EGFRm advanced NSCLC.

3. Raised $200 million in net proceeds, extending cash runway into Q4 2025.

4. Five-year strategic collaboration with MD Anderson to accelerate ivonescimab development in solid tumors.

5. Q2 2024 financial results: GAAP net loss of $60.4 million ($0.09 per share), Non-GAAP net loss of $34.3 million ($0.05 per share).

Summit Therapeutics (NASDAQ: SMMT) has announced it will host an earnings call on August 6, 2024, to discuss its second quarter 2024 financial results and provide an operational update. The conference call is scheduled for 9:00am ET, before the market opens. Investors and interested parties can access the live webcast through the company's website at www.smmttx.com. An archived version of the session will also be available on the website for those unable to attend the live call.

Summit Therapeutics (NASDAQ: SMMT) and MD Anderson Cancer Center have announced a five-year strategic collaboration to accelerate the development of ivonescimab, a potential first-in-class PD-1 / VEGF bispecific antibody. The partnership aims to explore additional opportunities for ivonescimab in various solid tumors beyond its current development plan.

MD Anderson will lead multiple clinical trials to evaluate ivonescimab's safety and potential clinical benefit, including biomarker identification. Early work may focus on renal cell carcinoma, colorectal cancer, skin cancer, breast cancer, and glioblastoma. The collaboration leverages MD Anderson's clinical infrastructure and research expertise alongside Summit's innovative drug candidate.

Ivonescimab has shown promise in recent Phase III non-small cell lung cancer trials (HARMONi-A and HARMONi-2) and Phase II studies in other solid tumors. The partnership aims to rapidly expand the drug's development program and bring this innovative immunotherapy and anti-angiogenic treatment to patients who may benefit.

Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards of options to purchase up to 330,000 shares of common stock to six new employees. These awards, approved by the Compensation Committee, were given as an incentive for the new hires under Nasdaq Listing Rule 5635(c)(4). The options, granted on June 28, 2024, have a 10-year term with an exercise price of $7.80 per share, matching the closing price on the grant date. The options will vest in equal annual installments over four years and are governed by stock option agreements.